Maintenance notice: Some features that submit or update information are temporarily disabled while we migrate the website. You can continue browsing normally. Thank you for your understanding.
Cartiva’s implant is an organic polymer-based biomaterial to mimic biologic cartilage. The device, according to an FDA announcement, is to be indicated for treatment of degenerative and post-traumatic arthritis in the first metatarsophalangeal joint in the presence of good bone stock along with the following clinical conditions: hallux valgus or hallux limitus, hallux rigidus, and an unstable or painful metatarsophalangeal joint.
The FDA intends to make background material available to the public no later than two business days before the meeting.
If you have orthopedic information that you would like to share with the Orthogate Community, please register/login and submit your news, event, job, article, case or workshop from the Submit Content menu under the My Account area. Learn more!
Improving orthopaedic care, education and research using Internet technologies